| Zeit | Aktuelle Nachrichten Sprache:
Alle DE EN | Leser | Medien | ||
|---|---|---|---|---|---|
| Mo | INTELLIGENT BIO SOLUTIONS INC. - 8-K, Current Report | 4 | SEC Filings | ||
| 25.02. | INTELLIGENT BIO SOLUTIONS INC. - 8-K, Current Report | 2 | SEC Filings | ||
| INTELLIGENT BIO SOLUTIONS Aktie jetzt für 0€ handeln | |||||
| 25.02. | INBS receives first reader shipment from Syrma Johari partnership | 3 | Investing.com | ||
| 25.02. | Intelligent Bio Solutions erhält erste Lieferung von Lesegeräten aus Syrma-Johari-Partnerschaft | 2 | Investing.com Deutsch | ||
| 25.02. | Intelligent Bio Solutions, Inc.: Intelligent Bio Solutions Successfully Manufactures and Ships First Readers with New Partner, Accelerating Scale and Driving Gross Margin Expansion in Anticipation of Planned U.S. Entry | 1 | GlobeNewswire (USA) | ||
| 24.02. | Intelligent Bio Solutions, Inc.: Intelligent Bio Solutions Partners with Bouygues UK, Part of Multi-Billion Dollar Global Construction Giant Bouygues Construction, for UK Drug Testing Rollout | 4 | GlobeNewswire (USA) | ||
| 12.02. | INTELLIGENT BIO SOLUTIONS INC. - 8-K, Current Report | 3 | SEC Filings | ||
| 12.02. | Intelligent Bio Solutions, Inc.: Intelligent Bio Solutions Reports Record Fiscal Second Quarter Revenue Growth of 48% with Reader Sales Surging 104% Year-Over-Year | 316 | GlobeNewswire (Europe) | First half fiscal 2026 revenue surpasses $2 million, up 36% year-over-year Reader sales more than double to 104% year-over-year for the second quarter, demonstrating razor-razorblade model momentum... ► Artikel lesen | |
| 12.02. | INTELLIGENT BIO SOLUTIONS INC. - 10-Q, Quarterly Report | 3 | SEC Filings | ||
| 05.02. | INTELLIGENT BIO SOLUTIONS INC. - 8-K, Current Report | 3 | SEC Filings | ||
| 05.02. | Intelligent Bio Solutions, Inc.: Intelligent Bio Solutions Expects to Report Fiscal Second Quarter 2026 Revenue Growth of Approximately 48% Year-Over-Year, Surpassing $2 Million in Total Revenue for First Half of Fiscal Year | 7 | GlobeNewswire (USA) | ||
| 28.01. | INTELLIGENT BIO SOLUTIONS INC. - 8-K, Current Report | 10 | SEC Filings | ||
| 28.01. | Intelligent Bio Solutions begins clinical studies for FDA clearance | 2 | Investing.com | ||
| 28.01. | Intelligent Bio Solutions, Inc.: Intelligent Bio Solutions Initiates Additional Clinical Studies for FDA 510(k) Submission Supporting Planned Entry into Multi-Billion Dollar U.S. Market | 159 | GlobeNewswire (Europe) | Clinical studies designed to support FDA clearance and planned commercial launch into the world's largest drug screening market Company anticipates full data analysis by the end of March 2026; data... ► Artikel lesen | |
| 08.01. | INTELLIGENT BIO SOLUTIONS INC. - 8-K, Current Report | 6 | SEC Filings | ||
| 02.01. | Intelligent Bio Solutions sichert sich 10 Millionen US-Dollar durch Privatplatzierung | 5 | Investing.com Deutsch | ||
| 02.01. | Intelligent Bio Solutions closes $10 million private placement | 4 | Investing.com | ||
| 02.01. | Intelligent Bio Solutions, Inc.: Intelligent Bio Solutions Announces Closing of $10.0 Million Private Placement Priced At-the-Market Under Nasdaq Rules | 3 | GlobeNewswire (USA) | ||
| 02.01. | INBS Stock Surges 132.4% on New Manufacturing Partnership | 4 | Zacks | ||
| 02.01. | Stock Market Today: S&P 500, Dow Futures Gain On The First Trading Day Of 2026- Baidu, Rubico, Intelligent Bio Solutions In Focus | 14 | Benzinga.com |
| Unternehmen / Aktien | Aktienkurs | % | Top-Nachrichten | ||
|---|---|---|---|---|---|
| ECKERT & ZIEGLER | 14,130 | 0,00 % | EQS-DD: Eckert & Ziegler SE: Dr. Harald Hasselmann, Zuteilung von 62.541 Aktien als Vergütungsbestandteil im Rahmen der Vorstandsvergütung (eigene Aktien des Emittenten). Es handelt sich um ... | Meldung und öffentliche Bekanntgabe der Geschäfte von Personen, die Führungsaufgaben wahrnehmen, sowie in enger Beziehung zu ihnen stehenden Personen
24.03.2026 / 10:04... ► Artikel lesen | |
| DRAEGERWERK | 93,30 | 0,00 % | EQS-News: Drägerwerk AG & Co. KGaA: Dräger mit guter Auftragsentwicklung, Rekordumsatz und deutlicher Gewinnsteigerung im Geschäftsjahr 2025 - dritte Dividendenerhöhung in Folge | EQS-News: Drägerwerk AG & Co. KGaA
/ Schlagwort(e): Jahresbericht/Dividende
Drägerwerk AG & Co. KGaA: Dräger mit guter Auftragsentwicklung, Rekordumsatz und deutlicher Gewinnsteigerung... ► Artikel lesen | |
| TELADOC HEALTH | 4,716 | +0,32 % | Teladoc Health Q4 Loss Narrows | WASHINGTON (dpa-AFX) - Teladoc Health, Inc. (TDOC) on Wednesday reported a fourth-quarter net loss of $25.1 million, or $0.14 per share, compared to $48.4 million or $0.28 per share last year.Fourth-quarter... ► Artikel lesen | |
| ROKU | 82,72 | +0,06 % | Roku Expands Howdy Streaming Service To Prime Video In U.S. | NEW DELHI (dpa-AFX) - Roku (ROKU) announced the launch of Howdy, its ad-free subscription video-on-demand (SVOD) streaming service, now available as a subscription on Prime Video in the U.S.... ► Artikel lesen | |
| HIMS & HERS HEALTH | 18,555 | -0,27 % | Hims & Hers Expands Integrated Digital Healthcare Ecosystem | ||
| BICO GROUP | 1,588 | -0,13 % | BICO Group AB: BICO Group AB has divested the Finnish property for a total of EUR 3.5m | BICO Group AB ("BICO") has completed the divestment of its property in Oulu, Finland, through the sale of BICO Real Estate Oy to Logistea AB ("Logistea"). The total sales price amounts to EUR 3.5m,... ► Artikel lesen | |
| SERNOVA BIOTHERAPEUTICS | 0,092 | -4,17 % | Sernova Biotherapeutics: Sernova Biotherapeutics Announces Close of Non-Brokered Private Placement Financing | Toronto, Ontario and Boston, Massachusetts--(Newsfile Corp. - March 24, 2026) - Sernova Biotherapeutics (TSX: SVA) (OTC Pink: SEOVF) (FSE: PSH0) ("Sernova" or the "Company"), a leading regenerative... ► Artikel lesen | |
| GERATHERM MEDICAL | 2,630 | -4,01 % | Geratherm Medical wechselt vom Börsensegment Scale in den Open Market | Die Geratherm Medical AG beendet zum 27. April 2026 die Einbeziehung ihrer Aktien in das Börsensegment Scale der Frankfurter Wertpapierbörse und wechselt ins Basic Board am Open Market. Die Börsennotierung... ► Artikel lesen | |
| SYNLAB | 12,710 | 0,00 % | EQS-News: SYNLAB AG: Weitere Investitionen in Italien für modernste Diagnostik und Patientenkomfort | EQS-News: SYNLAB
/ Schlagwort(e): Strategische Unternehmensentscheidung
Weitere Investitionen in Italien für modernste Diagnostik und Patientenkomfort
23.10.2025... ► Artikel lesen | |
| ALIGN TECHNOLOGY | 154,20 | -0,16 % | ROUNDUP/Aktien New York: Weitere Verluste - Ölpreisschub schürt Inflationsangst | NEW YORK (dpa-AFX) - An den New Yorker Aktienmärkten gibt es am Donnerstag aus Angst vor einer weiteren Eskalation an den Öl- und Gasmärkten erneut Verluste. Deutlich steigende Preise im Zuge des Iran-Kriegs... ► Artikel lesen | |
| NUGEN MEDICAL DEVICES | 0,017 | +16,00 % | NuGen Medical Devices Inc.: NuGen Medical Devices Inc. Provides Update on Health Canada License | Toronto, Ontario--(Newsfile Corp. - February 5, 2026) - NuGen Medical Devices Inc. (TSXV: NGMD) ("NuGen" or the "Company") is initiating a temporary halt on its devices in Canada due to the lapse... ► Artikel lesen | |
| PLUS THERAPEUTICS | 0,238 | -3,52 % | Plus Therapeutics Inc.: Plus Therapeutics to Present New Analysis at ISPOR Showing CNSide May Reduce Leptomeningeal Metastases Healthcare Costs by 40% | ||
| HEALWELL AI | 0,500 | -2,91 % | HEALWELL AI erzielt Rekordumsatz und schließt erstes Jahr mit positivem bereinigtem EBITDA ab, da die globale KI-Plattformstrategie greift | - Rekordumsatzwachstum - HEALWELL erzielte im Geschäftsjahr 2025 einen Rekordjahresumsatz aus
fortlaufenden Betrieben in Höhe von ca. 103,8 Millionen Dollar. Dies entspricht einem Anstieg... ► Artikel lesen | |
| ATOSSA THERAPEUTICS | 0,001 | -100,00 % | Atossa Therapeutics Inc: Atossa Therapeutics Strengthens Clinical Leadership Team with the Addition of Two Experienced Biopharma Executives | Kathy Puyana Theall, M.D. and Adebola Giwa, M.D. bring deep expertise across oncology, rare diseases, and global clinical development to support advancement of Atossa's... ► Artikel lesen | |
| SPINEWAY | 0,157 | 0,00 % | Spineway: 2025 annual results | Ecully, February 17, 2026 - 7:00 p.m. SPINEWAY2025 annual results Revenue up 4%Improved resultsStronger growth potential Condensed consolidated income statement20252024Pro forma* 2024ReportedIn thousands... ► Artikel lesen |